Previous 10 | Next 10 |
2023-08-10 10:27:32 ET Gainers: LifeMD ( LFMD ) +20% . Precigen ( PGEN ) +19% . Repare Therapeutics ( RPTX ) +16% . Cosmos Health ( COSM ) +13% . GoodRx Holdings ( GDRX ) +13% . Losers: Galera Therapeutics ( GRTX ) -...
2023-08-09 17:46:16 ET Repare Therapeutics press release ( NASDAQ: RPTX ): Q2 GAAP EPS of -$0.28 beats by $0.52 . Revenue of $30.25M (+4414.9% Y/Y) beats by $22.57M . Cash and cash equivalents and marketable securities as of June 30, 2023 were $280.7 million, w...
Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthc...
Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed partial response and several patients with long stable disease Identified both inte...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent a...
Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to pr...
Repare Therapeutics Inc., (Nasdaq: RPTX), (“Repare”, or “the Company”), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr...
2023-05-19 17:30:11 ET Gainers: WISeKey International Holding ( WKEY ) +6% . Viracta Therapeutics ( VIRX ) +5% . Fossil Group ( FOSL ) +5% . OmniAb ( OABI ) +5% . Lifecore Biomedical ( LFCR ) +4% . Losers: Jupiter Wellnes...
2023-05-09 17:39:17 ET Repare Therapeutics press release ( NASDAQ: RPTX ): Q1 GAAP EPS of -$0.83 misses by $0.03 . Revenue of $5.67M (+1282.9% Y/Y) misses by $0.45M . For further details see: Repare Therapeutics GAAP EPS of -$0.83 misses by $0.03, revenue...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...